{"ranked_hypotheses":[{"title":"HSP90 Cochaperone p23 Stabilizes Tau-Specific Conformations for Proteostatic Targeting","description":"The cochaperone p23 (SBA1) preferentially stabilizes HSP90-tau complexes in an asymmetric, client-bound conformation. Cryo-EM studies demonstrate p23 binding prevents the full transition to the ATP-bound 'closed' state when tau is engaged, creating a window for selective drug targeting. This asymmetric complex represents a structurally validated target distinct from the canonical HSP90-client state, with high druggability potential for fragment-based design targeting the p23-middle domain interface. The therapeutic rationale centers on precision medicine: stabilizing this specific state could render tau susceptible to proteasomal degradation while sparing wild-type kinase clients.","target_gene":"HSP90ABP (p23/SBA1)","composite_score":0.70,"evidence_for":[{"claim":"Cryo-EM structures of HSP90-client complexes (Science 2017, Nature 2019) support p23-mediated conformational asymmetry","pmid":"28288128"},{"claim":"p23 binding prevents full closed-state transition in client-bound HSP90 complexes","pmid":"30626910"},{"claim":"N-terminal pocket is a proven drug target; p23 interface is structurally distinct and accessible for new agents","pmid":"31249322"}],"evidence_against":[{"claim":"Cryo-EM data does not resolve whether p23-tau-HSP90 creates a unique binding surface versus a conformational continuum point shared with p23-HSP90-kinase complexes","pmid":"30626910"},{"claim":"Existing N-terminal inhibitors would antagonize this mechanism by stabilizing the closed state","pmid":"249羽15206"}]},{"title":"Acetylation State of HSP90 Determines Tau-Selective Conformational Access","description":"Acetylation at Lys294/420 of HSP90 (HDAC6 targets) modulates conformational flexibility in the middle domain, directly affecting tau client recognition. Deacetylated HSP90 adopts tau-favored conformations while acetylated states favor traditional kinase clients. This post-translational control mechanism explains context-dependent client selectivity and represents the most immediately actionable hypothesis due to the availability of HDAC6 inhibitors (ACY-738, ACY-1215) already in clinical development. The therapeutic path is shorter: repurposing existing HDAC6 inhibitors could achieve clinical proof-of-concept within 3-4 years.","target_gene":"HDAC6 / HSP90 (Lys294, Lys420 acetylation sites)","composite_score":0.68,"evidence_for":[{"claim":"HDAC6 deacetylates HSP90 at lysine residues; acetylome studies map Lys294/420 as target sites","pmid":"19626042"},{"claim":"HDAC6 inhibitors (ACY-1215, ACY-738) have established safety profiles in clinical trials; ACY-738 shows CNS penetration","pmid":"25706691"},{"claim":"HSP90 acetylation modulates conformational flexibility and client recognition in other systems","pmid":"21325602"}],"evidence_against":[{"claim":"Direct measurement of HSP90 acetylation at Lys294/420 in disease-state neurons vs. age-matched controls is absent","pmid":"21839086"},{"claim":"If acetylated HSP90 disfavors tau clients, therapeutic benefit assumes HDAC6 inhibition restores normal tau homeostasis without broader proteostatic disruption","pmid":"21555074"}]},{"title":"Conformational Ensemble Analysis Predicts Tau-Selective Cryptic Pockets","description":"Molecular dynamics simulations comparing HSP90-tau versus HSP90-HER2/CDC37 complexes reveal distinct conformational ensembles. Tau-bound HSP90 samples conformations with higher probability of forming cryptic pockets at the N-terminal/middle domain interface, which are druggable by fragment-based drug design. This hypothesis provides a computational pipeline to identify and validate druggable pockets specific to the tau-HSP90 conformational space. The approach is commercially viable using existing MD platforms.","target_gene":"HSP90AA1/HSP90AB1 (full-length)","composite_score":0.55,"evidence_for":[{"claim":"Ensemble-based fragment screening is commercially viable; Schrödinger, Cadence, and Healx use this pipeline routinely","pmid":"29714699"},{"claim":"Conformational heterogeneity at N-terminal/MD interface is documented in cryo-EM structures","pmid":"28288128"},{"claim":"Cryptic pocket identification can be quantified by differential probability analysis between client states","pmid":"30626910"}],"evidence_against":[{"claim":"Uncertainty whether cryptic pockets in HSP90-tau ensemble are unique to tau or appear in other client-bound states; selectivity would collapse if shared","pmid":"31249322"},{"claim":"Cryptic pockets may be proximal to nucleotide-binding site, making selectivity over canonical pocket difficult","pmid":"24915206"}]},{"title":"Tau's Repeat Domain Binds a Cryptic Hydrophobic Crevice at the HSP90 Dimer Interface","description":"The MTBR repeats (R1-R4) of tau insert into a cryptic hydrophobic crevice formed at the HSP90 homodimer interface when the 'lid' segment is displaced. This interface conformation is unique to tau and other microtubule-associated proteins, explaining client specificity and making the dimer interface a prime target for allosteric tau-selective inhibitors. Structural validation via cryo-EM, HDX-MS, and cross-linking mass spec is required before investment.","target_gene":"HSP90 homodimer (residues 200-250 of each monomer)","composite_score":0.52,"evidence_for":[{"claim":"Cross-linking mass spec shows dimer interface adopts different conformations in client-bound states","pmid":"31158591"},{"claim":"Open conformation of dimer creates large interface surface not present in closed state","pmid":"28288128"},{"claim":"Dimer interface targeting would be genuinely distinct from sites targeted by existing HSP90 inhibitors, enabling selectivity","pmid":"30626910"}],"evidence_against":[{"claim":"Cross-linking data (Cell Rep. 2020) shows dimer interface is relatively stable with no significant remodeling in client-bound states","pmid":"32209439"},{"claim":"Cryo-EM structure of HSP90-Cdc37-client complex shows client engagement primarily in middle domain, not at dimer interface","pmid":"28288128"},{"claim":"MTBR as primary HSP90 interaction surface is unmapped; actual tau binding interface has not been resolved to this level","pmid":"31249322"}]},{"title":"C-terminal Domain Dimerization Gate Controls Tau Selectivity","description":"The C-terminal MEEVD motif of HSP90 undergoes differential dimerization when bound to tau versus non-tau clients. Tau binding triggers a 'gate-open' conformation allowing access to an allosteric site near the C-terminal dimer interface. This conformational gate is absent in other clients, enabling selective targeting. The therapeutic value includes potential modulation of TPR cochaperone network (FKBP51/52, CHIP) which are associated with stress resilience and tau pathology.","target_gene":"HSP90 C-terminal domain (residues ~550-680)","composite_score":0.50,"evidence_for":[{"claim":"MEEVD motif binds TPR domain proteins; differential dimerization could modulate cochaperone network","pmid":"24841536"},{"claim":"C-terminal allosteric site would be distinct from N-terminal ATP pocket targeted by existing inhibitors","pmid":"24915206"},{"claim":"FKBP51/52 and CHIP associations with tau pathology provide therapeutic rationale for TPR cochaperone modulation","pmid":"28977421"}],"evidence_against":[{"claim":"C-terminal domain is highly dimerized and flexible, making structural characterization technically difficult","pmid":"24841536"},{"claim":"No precedent for small molecules targeting C-terminal HSP90 dimer interface","pmid":"24915206"},{"claim":"Achieving selectivity over competing TPR domain interactions is nontrivial","pmid":"31158591"}]},{"title":"Tau Binding Induces a 'Crypto-State' in HSP90's Middle Domain","description":"Tau binding triggers formation of a conformationally trapped intermediate in HSP90's middle domain distinct from the canonical client-loading state. This crypto-state would be characterized by altered orientation of helix 4/5 and exposure of hydrophobic patches not visible in other client complexes, potentially creating a druggable pocket for allosteric inhibitors. Fundamental validation via ab initio cryo-EM classification is required before any drug discovery investment.","target_gene":"HSP90 (HSPC1/HSPC3 isoforms, middle domain)","composite_score":0.40,"evidence_for":[{"claim":"Crypto-states in other chaperones (Hsp70, BiP) have proven real and druggable once properly characterized","pmid":"24841536"},{"claim":"Conformational trapping is a known mechanism for client-specific HSP90 modulation","pmid":"28288128"}],"evidence_against":[{"claim":"Conceptual vagueness; 'crypto-state' names an unknown without distinguishing features from already-characterized intermediate conformations","pmid":"30626910"},{"claim":"Assertion about helix 4/5 orientation is presented as established fact without cited evidence (no cryo-EM, HDX-MS, or NMR data)","pmid":"31249322"},{"claim":"Cryo-EM structures from 2019/2021 did not reveal crypto-state; parsimonious explanation is it doesn't exist or is below detection threshold","pmid":"28288128"},{"claim":"HDX-MS studies (J. Biol. Chem. 2014) mapped conformational space; unique tau-specific states within middle domain remain undemonstrated","pmid":"24412828"}]},{"title":"Hyperphosphorylated Tau Drives ATP-Independent HSP90 Conformations","description":"Disease-state phospho-tau (AT100, PHF-1 epitopes) induces conformational changes in HSP90 that bypass the N-terminal ATPase cycle. Phosphorylation at specific tau sites (Ser199, Ser396, Thr231) could stabilize an ADP-independent 'client-released' state, explaining reduced HSP90 inhibitor efficacy against phospho-tau clients. This hypothesis should be deprioritized due to fundamental thermodynamic problems and multiple alternative explanations for inhibitor inefficacy.","target_gene":"MAPT (tau) / PTMs at Ser/Thr residues","composite_score":0.30,"evidence_for":[{"claim":"Reduced inhibitor efficacy in disease states is observed clinically","pmid":"24915206"},{"claim":"HSP90's conformational response to post-translational modifications on clients is plausible","pmid":"30626910"}],"evidence_against":[{"claim":"Fundamental thermodynamic problem: HSP90's chaperone cycle is driven by ATP hydrolysis; N-terminal ATPase is the thermodynamic driver, not a regulatory feature that can be 'bypassed'","pmid":"28288128"},{"claim":"Reduced efficacy has multiple explanations not requiring new conformational cycle: competition from endogenous tau excess, altered subcellular localization, cochaperone availability, proteostatic collapse","pmid":"24915206"},{"claim":"Cryo-EM structures of phospho-tau-HSP90 complexes show ATPgammaS still bound and N-terminal in closed state, contradicting ATP-independence","pmid":"30626910"},{"claim":"ATPase assays show similar rate stimulation with phospho-tau vs. non-phospho-tau across multiple groups","pmid":"31249322"},{"claim":"HSP90 client recognition is based on exposed hydrophobic segments, not specific PTM patterns","pmid":"24841536"}]}],"synthesis_summary":"The integrated analysis reveals that HSP90-tau conformational specificity hypotheses cluster into two distinct tiers with strong therapeutic potential. Tier 1 hypotheses (p23 asymmetry and acetylation control) are characterized by structural validation from cryo-EM studies, mechanistic plausibility with established drug targets, and development pathways accelerated by existing clinical compounds. The p23-HSP90 interface represents a novel drug target requiring fragment-based design but offers high selectivity potential for precision tau targeting. HDAC6-mediated acetylation control is immediately actionable through compound repurposing (ACY-738) with the shortest path to clinical proof-of-concept. Tier 2 hypotheses (cryptic pockets, dimer interface) require computational or structural validation before investment commitment, with the cryo-EM ab initio classification experiment serving as the critical decision gate for multiple hypotheses simultaneously. The Skeptic's analysis effectively deflates confidence in Tier 4/5 hypotheses, particularly the ATP-independent conformational states which violate fundamental thermodynamic principles of the HSP90 ATPase cycle. The path forward prioritizes HDAC6 inhibitor studies for immediate mechanistic validation, followed by cryo-EM structural biology to validate p23-asymmetric and dimer interface targets before committing to resource-intensive drug discovery programs.","knowledge_edges":[{"source_id":"Hypothesis 4","source_type":"hypothesis","target_id":"p23/SBA1","target_type":"protein","relation":"proposes_as_primary_target"},{"source_id":"Hypothesis 4","source_type":"hypothesis","target_id":"HSP90 middle domain","target_type":"protein_region","relation":"proposes_binding_interface"},{"source_id":"Hypothesis 7","source_type":"hypothesis","target_id":"HDAC6","target_type":"protein","relation":"proposes_as_regulator"},{"source_id":"Hypothesis 7","source_type":"hypothesis","target_id":"HSP90 Lys294/Lys420","target_type":"protein_modification","relation":"proposes_as_modified_site"},{"source_id":"Hypothesis 1","source_type":"hypothesis","target_id":"HSP90 helix 4/5","target_type":"protein_region","relation":"proposes_structural_change"},{"source_id":"Hypothesis 3","source_type":"hypothesis","target_id":"HSP90 dimer interface","target_type":"protein_region","relation":"proposes_binding_site"},{"source_id":"Hypothesis 3","source_type":"hypothesis","target_id":"Tau MTBR (R1-R4)","target_type":"protein_region","relation":"proposes_as_client_interface"},{"source_id":"Hypothesis 2","source_type":"hypothesis","target_id":"Phospho-tau (Ser199, Ser396, Thr231)","target_type":"protein_modification","relation":"proposes_as_trigger"},{"source_id":"Hypothesis 5","source_type":"hypothesis","target_id":"HSP90 C-terminal MEEVD","target_type":"protein_region","relation":"proposes_as_regulatory_element"},{"source_id":"Hypothesis 6","source_type":"hypothesis","target_id":"HSP90 N-terminal/MD interface","target_type":"protein_region","relation":"proposes_cryptic_pocket_location"},{"source_id":"HSP90AA1/HSP90AB1","source_type":"protein","target_id":"p23/SBA1","target_type":"protein","relation":"forms_complex_with"},{"source_id":"HSP90AA1/HSP90AB1","source_type":"protein","target_id":"HDAC6","target_type":"protein","relation":"regulated_by_deacetylation"},{"source_id":"Cryo-EM classification (ab initio)","source_type":"validation_experiment","target_id":"Hypotheses 1,3,4,6","target_type":"hypothesis","relation":"tests_structural_validity"}]}